Anavex Life Sciences Corp.
AVXL· Nasdaq
AVXLAnavex Life Sciences Corp.
Filed Aug 12, 2021 · 10-Q · 43 days after period end · 0001731122-21-001347
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Net Income | -$10.18M | -$6.49M | -$6.52M | -$2.85M |
| EPS Diluted | -$0.14 | -$0.11 | -$0.13 | -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Jun 30, 2021 · filed Aug 12, 2021 · 43 d after period end
